Clinical Factors Associated With Long-Term Benefit in Patients With mRCC Treated With Axitinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clin Genitourin Cancer 2021 Oct 20;[EPub Ahead of Print], Á Pinto, O Reig, C Iglesias, E Gallardo, X García-Del Muro, T Alonso, G Anguera, C Suárez, J Muñoz-Langa, L Villalobos-León, Á Rodríguez-Sánchez, N Lainez, E Martínez-Ortega, M Campayo, A Velastegui, A Rodriguez-Vida, JC Villa-Guzmán, MJ Méndez-Vidal, G Rubio, I García, L Capdevila, J Lambea, S Vázquez, O Fernández, S Hernando-Polo, S Cerezo, C Santander, R García-Marrero, F Zambrana, A González-Del Alba, M Lazaro-Quintela, D Castellano, I Chirivella, U Anido, A Viana, A García, M Sotelo, MG Arévalo, J García-Donas, C Hernández, MV Bolós, J Llinares, MA ClimentFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.